

Imatinib to the Rescue: Bleeding GIST Refractory to Standard Endoscopic Hemostatic Therapies

Amberly Vaughan, MS4¹; Azfar Syed, DO, MBA²; Jeffrey Laczek, MD² Uniformed Services University¹; Department of Gastroenterology², National Capital Consortium, Bethesda, MD






INTRODUCTION

- Bleeding in Gastrointestinal stromal tumor (GIST) portends a poor prognosis and is more likely in larger tumors with higher mitotic rates. ³
- Hemostatic powder is a new modality to control gastrointestinal hemorrhage.
- Imatinib is a tyrosine kinase inhibitor used in adjuvant/neoadjuvant treatment of GIST.
- This case highlights the benefit of imatinib and hemostatic powder in gastrointestinal hemorrhage secondary to a GIST.

CASE REPORT

- 50-year-old female with presented with hematemesis and hemoglobin of 6.5g/dL. CT scan showed a 3cm mass on the lesser curve of the stomach.
- Esophagogastroduodenoscopy (EGD) revealed an actively oozing, ulcerated subepithelial mass close to the gastroesophageal junction (Figure 1). Hemostatic powder temporized the oozing.
- Biopsy via endoscopic ultrasound-guided-fine-needle aspiration showed spindle cells with positive immunohistochemical staining for c-KIT and DOG-1, consistent with GIST (Figure 3). Mitotic rate was 1/20hpf.
- Ongoing melena and transfusion requirement prompted repeat EGD, showing continued oozing. After failed endoscopic clipping, hemostasis was achieved with hemostatic powder (Figure 2).
- She was started on imatinib 600mg per day with cessation of bleeding. Definitive surgical therapy is pending response to imatinib.





DISCUSSION

- Achieving hemostasis with standard endoscopic therapies is difficult for bleeding GISTs, which are very vascular.⁴
- Hemostatic spray offers a new option to temporize the bleeding from GISTs.¹
- Imatinib is well established in neoadjuvant role to shrink tumor size or as adjuvant therapy for GIST. Use of imatinib in treatment of GIST related hemorrhage is less well established.
- This case demonstrates the potential role for imatinib in bleeding GIST, providing an alternative to more high-risk options, such as embolization or emergent surgery.




Figure 3: Spindle Cells on cytology consistent with GIST

ACKNOWLEDGMENTS

We are very grateful for the contribution of Peter N. Bonneau, MD, Maj, USAF for providing pathology imaging (Figure 3).

REFERENCES

- 1. Alawawdeh F, Al-Tkrit A, Aneeb M, Mekaiel A, Mehta A. Gastrointestinal Stromal Tumor: An Uncommon but Serious Cause of Gastrointestinal Bleeding. J Med Cases. 2021;12(2):74-78. doi:10.14740/jmc3631
- 2. Hecker A, Hecker B, Bassaly B, et al. Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review. World J Surg Oncol. 2010;8:47. Published 2010 Jun 2. doi:10.1186/1477-7819-8-47
- 3. Liu Q, Li Y, Dong M, Kong F, Dong Q. Gastrointestinal Bleeding Is an Independent Risk Factor for Poor Prognosis in GIST Patients. *Biomed Res Int*. 2017;2017:7152406. doi:10.1155/2017/7152406
- 4. Liu Q, Kong F, Zhou J, Dong M, Dong Q. Management of hemorrhage in gastrointestinal stromal tumors: a review. Cancer Manag Res. 2018 Apr 12;10:735-743. doi: 10.2147/CMAR.S159689. PMID: 29695930; PMCID: PMC5903846.